…
Probiotec Limited engages in the development, manufacture, packing, distribution, and sale of prescription and over the counter pharmaceuticals, complementary medicines and consumer health products, and fast-moving consumer products in Australia and internationally. The company provides contract manufacturing services for solid dose tablets, capsules, and caplets; tablets coatings; blister packs, bottles, sachets, tubs, and tubes; liquids, creams, gels, lotions, ointments, and powders and powder blends. It is also involved in analytical and stability testing services; new product formulation and production trials, and ongoing research and development services; and packaging options for human and animal nutrition products, as well as manufactures and exports a range of nutraceuticals and functional ingredient raw materials. The company was incorporated in 1996 and is headquartered in Laverton North, Australia. As of June 18, 2024, Probiotec Limited operates as a subsidiary of PYFA Australia Pty Ltd.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Income before tax | 15.57M | 18.04M | 7.72M | 8.90M | 4.99M |
| Net income | 11.02M | 13.71M | 4.85M | 3.51M | 3.51M |
| Selling general administrative | 27.12M | 14.77M | 11.53M | 0.53M | 0.48M |
| Selling and marketing expenses | 13.76M | 11.45M | 8.19M | 7.96M | 9.23M |
| Gross profit | 64.34M | 57.24M | 38.70M | 31.78M | 25.75M |
| Reconciled depreciation | 16.77M | 14.77M | 8.17M | 5.31M | 3.30M |
| Ebit | 21.35M | 22.32M | 11.08M | 11.19M | 6.85M |
| Ebitda | 38.12M | 37.09M | 19.26M | 16.50M | 10.14M |
| Depreciation and amortization | 16.77M | 14.77M | 8.17M | 5.31M | 3.30M |
| Operating income | 20.73M | 19.55M | 11.02M | 10.83M | 6.85M |
| Other operating expenses | 192.68M | 160.01M | 109.43M | 96.03M | 75.89M |
| Interest expense | 5.77M | 4.29M | 3.36M | 2.29M | 1.85M |
| Tax provision | 4.56M | 4.33M | 2.65M | 2.46M | 0.78M |
| Net interest income | -5.77M | -4.29M | -3.36M | -2.29M | -1.85M |
| Extraordinary items | - | 0.00M | -0.22M | -2.94M | 7.59M |
| Income tax expense | 4.56M | 4.33M | 2.65M | 2.46M | 0.92M |
| Total revenue | 214.03M | 182.33M | 120.51M | 107.22M | 79.09M |
| Total operating expenses | 57.65M | 50.02M | 35.85M | 26.26M | 22.54M |
| Cost of revenue | 149.69M | 125.09M | 81.81M | 75.44M | 53.35M |
| Total other income expense net | 0.62M | 2.77M | 0.06M | 0.36M | -1.85M |
| Discontinued operations | - | - | -0.22M | -2.94M | 7.59M |
| Net income from continuing ops | 11.02M | 13.71M | 5.07M | 6.44M | 4.07M |
| Net income applicable to common shares | 11.02M | 13.71M | 4.85M | 3.51M | 11.33M |
| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Total assets | 235.44M | 237.91M | 230.88M | 134.06M | 106.37M |
| Intangible assets | 20.16M | 21.54M | 21.88M | 17.41M | 9.25M |
| Other current assets | 1.44M | 1.60M | 0.99M | 0.52M | 6.21M |
| Total liab | 148.30M | 158.86M | 162.26M | 73.55M | 56.52M |
| Total stockholder equity | 87.14M | 79.05M | 68.61M | 60.51M | 49.85M |
| Other current liab | 70.51M | 4.21M | 6.55M | 11.34M | 5.33M |
| Common stock | 53.18M | 51.29M | 50.69M | 43.74M | 33.61M |
| Capital stock | 53.18M | 51.29M | 50.69M | 43.74M | 33.61M |
| Retained earnings | 33.31M | 27.58M | 17.85M | 16.29M | 15.65M |
| Other liab | 19.27M | 23.10M | 27.98M | 13.77M | 11.09M |
| Good will | 64.54M | 64.54M | 62.36M | 25.54M | 8.17M |
| Other assets | 14.08M | 14.99M | 14.81M | 8.33M | 7.65M |
| Cash | 14.05M | 22.20M | 28.43M | 6.31M | 8.84M |
| Cash and equivalents | 14.05M | 22.20M | 28.43M | 6.31M | 8.84M |
| Total current liabilities | 93.69M | 51.43M | 44.43M | 25.65M | 19.18M |
| Current deferred revenue | -52.56M | 18.01M | 17.24M | -3.90M | - |
| Net debt | 73.85M | 70.79M | 68.87M | 31.72M | 21.87M |
| Short term debt | 52.56M | 8.65M | 7.44M | 3.90M | 4.47M |
| Short long term debt | 46.96M | 1.51M | 1.56M | 1.64M | 1.84M |
| Short long term debt total | 87.90M | 92.99M | 97.29M | 38.02M | 30.72M |
| Other stockholder equity | 0.65M | 0.18M | 0.07M | 0.48M | 0.59M |
| Property plant equipment | 60.99M | 62.21M | 64.05M | 36.59M | 34.23M |
| Total current assets | 75.67M | 74.63M | 67.78M | 46.19M | 47.07M |
| Net tangible assets | 2.44M | -7.03M | -15.63M | 17.56M | 32.43M |
| Net receivables | 36.39M | 31.23M | 24.45M | 22.94M | 18.76M |
| Long term debt | 0.00M | 46.96M | 48.42M | 9.66M | 3.23M |
| Inventory | 23.79M | 19.60M | 13.90M | 15.70M | 13.25M |
| Accounts payable | 23.18M | 20.55M | 13.20M | 14.32M | 9.38M |
| Accumulated other comprehensive income | 0.65M | 0.18M | 0.07M | 0.48M | 0.59M |
| Common stock total equity | - | - | - | 43.74M | 33.61M |
| Non currrent assets other | -145.69M | -148.29M | 0.00M | -79.54M | 16.40M |
| Non current assets total | 159.77M | 163.28M | 163.10M | 87.87M | 59.30M |
| Capital lease obligations | 40.94M | 44.53M | 47.32M | 26.72M | 25.65M |
| Long term debt total | 35.33M | 84.34M | 89.86M | 34.12M | 26.25M |
| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Investments | -13.74M | -16.47M | -35.86M | -24.95M | 30.06M |
| Change to liabilities | 2.63M | 9.16M | -1.17M | 3.61M | -3.41M |
| Total cashflows from investing activities | -13.74M | -16.47M | -35.86M | -24.95M | 30.06M |
| Net borrowings | -6.66M | -5.89M | 37.38M | 5.10M | -8.59M |
| Total cash from financing activities | -11.58M | -9.27M | 33.61M | 12.24M | -18.65M |
| Change to operating activities | 1.06M | -0.39M | -0.57M | 0.49M | -0.66M |
| Net income | 11.02M | 13.71M | 4.85M | 3.51M | 4.07M |
| Change in cash | -8.15M | -6.22M | 22.12M | -2.54M | 7.03M |
| Begin period cash flow | 22.20M | 28.43M | 6.31M | 8.84M | 1.82M |
| End period cash flow | 14.05M | 22.20M | 28.43M | 6.31M | 8.84M |
| Total cash from operating activities | 17.17M | 19.52M | 24.37M | 10.17M | -4.39M |
| Issuance of capital stock | 0.37M | 0.60M | - | 10.14M | 0.76M |
| Depreciation | 13.08M | 11.44M | 7.68M | 5.01M | 3.30M |
| Other cashflows from investing activities | -3.59M | -9.54M | -31.67M | -19.32M | 42.57M |
| Dividends paid | 5.29M | 3.98M | 3.77M | 2.99M | 5.07M |
| Change to inventory | -4.19M | -5.33M | 4.28M | -0.38M | -1.69M |
| Change to account receivables | -5.16M | -6.78M | 7.69M | -1.21M | -2.31M |
| Sale purchase of stock | 0.77M | 6.47M | -0.60M | -0.01M | -5.74M |
| Other cashflows from financing activities | -5.64M | -5.29M | 40.83M | 8.52M | 30.06M |
| Change to netincome | 0.07M | -2.32M | 0.04M | -0.54M | -10.52M |
| Capital expenditures | 10.14M | 6.93M | 4.19M | 5.63M | 12.51M |
| Change in working capital | -9.34M | -12.11M | 11.97M | -1.60M | 0.15M |
| Stock based compensation | 0.69M | 0.45M | 0.08M | - | - |
| Other non cash items | -6.93M | -5.62M | 11.84M | 3.26M | -14.63M |
| Free cash flow | 7.02M | 12.59M | 20.18M | 4.54M | -12.51M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
|
Stock Name
|
Change
(AUD) |
Price
(AUD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| AFP Aft Pharmaceuticals Ltd |
- -% |
3.59 | 29.92 | 18.18 | 1.48 | 4.37 | 2.05 | 18.56 |
| VLS Vita Life Sciences Ltd |
- -% |
2.70 | 13.50 | 42.73 | 1.52 | 2.62 | 1.19 | 7.17 |
| LGP Little Green Pharma Ltd |
- -% |
0.06 | - | 10.00 | 0.64 | 0.60 | 1.25 | 19.47 |
| MVP Medical Developments International Ltd |
- -% |
0.40 | 40.00 | 166.67 | 1.06 | 0.79 | 0.57 | 7.45 |
Probiotec Limited engages in the development, manufacture, packing, distribution, and sale of prescription and over the counter pharmaceuticals, complementary medicines and consumer health products, and fast-moving consumer products in Australia and internationally. The company provides contract manufacturing services for solid dose tablets, capsules, and caplets; tablets coatings; blister packs, bottles, sachets, tubs, and tubes; liquids, creams, gels, lotions, ointments, and powders and powder blends. It is also involved in analytical and stability testing services; new product formulation and production trials, and ongoing research and development services; and packaging options for human and animal nutrition products, as well as manufactures and exports a range of nutraceuticals and functional ingredient raw materials. The company was incorporated in 1996 and is headquartered in Laverton North, Australia. As of June 18, 2024, Probiotec Limited operates as a subsidiary of PYFA Australia Pty Ltd.
| Name | Title | Year Born |
|---|---|---|
| Mr. Wesley Stringer B.Comm, CPA, LLB (Hons) | CEO, MD & Exec. Director | NA |
| Mr. Jared Stringer B.Comm, BIT, CPA | CFO, Company Sec. & Financial Controller | NA |
| Ms. Julie McIntosh | Chief Operating Officer | NA |
| Mr. Alan Hong | Gen. Mang. of Accounting | NA |
| Mr. Dustin Stringer | Gen. Mang. of Marketing | NA |
| Ms. Annalinde Nickisch | Chief People Officer | NA |
| Ms. Jessica Walters | Chief Customer Officer | NA |
| Mr. Wesley Stringer B.Comm, CPA, LLB (Hons) | CEO, MD & Executive Director | NA |
| Mr. Jared Stringer B.Comm, BIT, CPA | CFO, Company Secretary & Financial Controller | NA |
| Mr. Alan Hong | General Manager of Accounting | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.